Two Multicenter, Randomized, Double-Blind, Parallel Group Comparison Studies of a Novel Foam Formulation of Halobetasol Propionate, 0.05% vs Its Vehicle in Adult Subjects With Plaque Psoriasis

被引:0
|
作者
Bhatia, Neal [1 ]
Gold, Linda Stein [2 ]
Kircik, Leon H. [3 ,4 ,5 ,6 ,7 ]
Schreiber, Rhonda [8 ]
机构
[1] Therapeut Clin Res, San Diego, CA 92161 USA
[2] Henry Ford Hlth Syst, Detroit, MI USA
[3] Icahn Sch Med Mt Sinai, New York, NY 10029 USA
[4] Indiana Univ, Med Ctr, Indianapolis, IN 46204 USA
[5] Phys Skin Care PLLC, Louisville, KY USA
[6] DermResearch PLLC, Louisville, KY USA
[7] Skin Sci PLLC, Louisville, KY USA
[8] Mayne Pharma LLC, Raleigh, NC USA
关键词
OINTMENT; CREAM;
D O I
暂无
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: A novel foam formulation of halobetasol propionate, 0.05% (HBP-Foam) has been developed to treat plaque psoriasis in patients who prefer a thermostable topical foam with low application shear that allows for easier coverage over large and/or hirsute areas than existing formulations. Objective:To determine the safety and effectiveness of HBP-Foam in subjects with plaque psoriasis. Methods: Two randomized, double-blind, vehicle-controlled clinical studies were conducted in 560 adult subjects with moderate to severe plaque psoriasis. Subjects applied the assigned test article to all psoriatic plaques twice daily for 14 days. The key efficacy measures were the proportion of subjects with "treatment success," defined as those subjects that achieved a score of 0 (clear) or 1 (almost clear) and at least a two-grade improvement compared to baseline for the Investigator's Global Assessment (IGA) and for the clinical signs of psoriasis (plaque elevation, scaling, and erythema) as well as pruritus. Safety measurements included adverse events and local skin reactions in the treatment area. Results: HBP-Foam was statistically superior to vehicle in achieving "Treatment Success" in 25.3% and 30.7% vs 3.9% and 74% (P<0.001) in Studies 1 and 2, respectively. Pruritus scores statistically improved by over 30% in HBP-Foam treated subjects. In addition, these subjects experienced a significant reduction in the clinical signs of psoriasis (plaque elevation, scaling, and erythema). In contrast, in the vehicle groups the decrease in psoriasis-related signs was generally not observed. Safety outcomes were unremarkable and similar in both the HBP-Foam and vehicle treatment groups. Conclusions:These results demonstrate the safety and effectiveness of HBP-Foam in the treatment of plaque psoriasis. Furthermore, this novel foam formulation has demonstrable for its ease of application over large and/or hairy treatment areas.
引用
收藏
页码:790 / 796
页数:7
相关论文
共 50 条
  • [41] A multicenter, randomized, double-blind, active-comparator, placebo-controlled, parallel-group comparison of the incidence of endoscopic gastric and duodenal ulcer rates with valdecoxib or naproxen in healthy subjects aged 65 to 75 years
    Goldstein, JL
    Alsenberg, J
    Lanza, F
    Schwartz, H
    Sands, GH
    Berger, MF
    Pan, S
    CLINICAL THERAPEUTICS, 2006, 28 (03) : 340 - 351
  • [42] Safety of Ozanimod Versus Interferon β-1a in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B)
    Cree, Bruce
    Bar-Or, Amit
    Comi, Giancarlo
    Selmaj, Krzysztof
    Arnold, Douglas
    Steinman, Lawrence
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva
    Sheffield, James
    Raghupathi, Kartik
    Kappos, Ludwig
    Cohen, Jeffrey
    NEUROLOGY, 2018, 90
  • [43] Two randomized, double-blind, placebo-controlled, parallel-group, fixed-dose, multicenter studies assess the efficacy and safety of daily oral administration of 10 mg YM905 versus placebo in male and female subjects with overactive bladder
    Gittelman, M
    Chu, FM
    Klimberg, I
    Fincher, R
    Smith, N
    Tempel, D
    Ridge, S
    JOURNAL OF UROLOGY, 2003, 169 (04): : 349 - 349
  • [44] A Novel Highly Bioavailable Curcumin Formulation Improves Symptoms and Diagnostic Indicators in Rheumatoid Arthritis Patients: A Randomized, Double-Blind, Placebo-Controlled, Two-Dose, Three-Arm, and Parallel-Group Study
    Amalraj, Augustine
    Varma, Karthik
    Jacob, Joby
    Divya, Chandradhara
    Kunnumakkara, Ajaikumar B.
    Stohs, Sidney J.
    Gopi, Sreeraj
    JOURNAL OF MEDICINAL FOOD, 2017, 20 (10) : 1022 - 1030
  • [45] Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies
    Omboni, Stefano
    Malacco, Ettore
    Manion, Jean-Michel
    Volpe, Massimo
    Zanchetti, Alberto
    JOURNAL OF HYPERTENSION, 2012, 30 (07) : 1468 - 1477
  • [46] Comparison of efficacy and tolerability of amlodipine orotate versus amlodipine besylate in adult patients with mild to moderate hypertension: A multicenter, randomized, double-blind, placebo-controlled, parallel-group, 8-week follow-up, noninferiority trial
    Hong, Soon Jun
    Ahn, Tae-Hoon
    Baek, Sang-Hong
    Cho, Wook-Hyun
    Jeon, Hyee-Kyoung
    Kyun, Jun
    Yoon, Myeong Ho
    Lee, Kwan Jeh
    Lim, Do-Sun
    CLINICAL THERAPEUTICS, 2006, 28 (04) : 537 - 551
  • [47] Efficacy and safety profiles of a new S(-)-amlodipine nicotinate formulation versus racemic amlodipine besylate in adult Korean patients with mild to moderate hypertension:: An 8-week, multicenter, randomized, double-blind, double-dummy, parallel-group, phase III, noninferiority clinical trial
    Kim, Sung Ai
    Park, Sungha
    Chung, Namsik
    Lim, Do-Sun
    Yang, Joo-Young
    Oh, Byung-Hee
    Tahk, SeungJea
    Ahn, Tae-Hoon
    CLINICAL THERAPEUTICS, 2008, 30 (05) : 845 - 857
  • [48] Efficacy of Ozanimod Versus Interferon β-1a by Prior Treatment and Baseline Disability in Two Multicenter, Randomized, Double-Blind, Parallel-Group, Active-Controlled, Double-Dummy Phase 3 Studies in Relapsing Multiple Sclerosis (SUNBEAM and RADIANCE Part B)
    Kappos, Ludwig
    Selmaj, Krzysztof
    Bar-Or, Amit
    Comi, Giancarlo
    Arnold, Douglas
    Steinman, Lawrence
    Hartung, Hans-Peter
    Montalban, Xavier
    Havrdova, Eva
    Sheffield, James
    Raghupathi, Kartik
    Cree, Bruce
    Cohen, Jeffrey
    NEUROLOGY, 2018, 90
  • [49] A Single-Tablet Fixed-Dose Combination of Racemic Ibuprofen/Paracetamol in the Management of Moderate to Severe Postoperative Dental Pain in Adult and Adolescent Patients: A Multicenter, Two-Stage, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Factorial Study
    Mehlisch, Donald R.
    Aspley, Sue
    Daniels, Stephen E.
    Southerden, Kristin A.
    Christensen, Kyle S.
    CLINICAL THERAPEUTICS, 2010, 32 (06) : 1033 - 1049
  • [50] Efficacy and safety of 25 and 50 μg desmopressin orally disintegrating tablets in Japanese patients with nocturia due to nocturnal polyuria: Results from two phase 3 studies of a multicenter randomized double-blind placebo-controlled parallel-group development program
    Yamaguchi, Osamu
    Juul, Kristian, V
    Falahati, Ali
    Yoshimura, Toru
    Imura, Futoshi
    Kitamura, Mikiya
    LUTS-LOWER URINARY TRACT SYMPTOMS, 2020, 12 (01) : 8 - 19